ICYMI: Eli Lilly's New Weight Loss Pill

Novi is an AI shopping optimization platform for consumer packaged goods (CPG). It seeks to help retailers and brands ensure their products can be accurately found, trusted, and recommended by AI assistants such as ChatGPT and Claude by verifying and structuring SKU-level product ...  Show more

Watch Bloomberg Businessweek LIVE every day on YouTube: http://bit.ly/3vTiACF.President Donald Trump’s push to end the war in Ukraine faced new complications on Monday when Vladimir Putin said he would revise his country’s negotiating position after the Russian leader claimed Ukr ...  Show more

Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.

Why GLP-1 Drugs Are in Demand 

Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ...

Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ...  Show more

Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the w ...